Increased depressor response to N-arachidonoyl-dopamine during high salt intake: Role of the TRPV1 receptor

Journal of Hypertension

Volumn 25, Issue 12, 2007, Pages 2426-2433

  Wang, Youping ^a   Wang, Donna H ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

Blood pressure; Calcitonin gene related peptide; N arachidonoyldopamine; Sensory nerves; Transient receptor potential vanilloid type 1 channels

Indexed keywords

CALCITONIN GENE RELATED PEPTIDE; CALCITONIN GENE RELATED PEPTIDE[8-37]; CAPSAICIN; CAPSAZEPINE; DOPAMINE DERIVATIVE; N ARACHIDONOYLDOPAMINE; RIMONABANT; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY CATHETERIZATION; ARTICLE; CONTROLLED STUDY; DEPRESSOR RESPONSE; DRUG MECHANISM; HIGH SODIUM INTAKE; HYPERTENSION; MALE; MEAN ARTERIAL PRESSURE; MESENTERIC ARTERY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; RADIOIMMUNOASSAY; RAT; RECEPTOR INTRINSIC ACTIVITY; WESTERN BLOTTING;

EID: 35848966560     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e3282efd1bf     Document Type: Article

References (41)

1. Caterian MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 1997; 389:816-824.
2. Wimalawansa SJ. Calcitonin gene-related peptide and its receptor: molecular genetics, physiology, pathophysiolgy, and therapeutic potentials. Endocr Rev 1996; 17:533-585.
3. Szallasi A, Blumberg PM. Vanilloid (Capsaicin) receptors and mechanisms. Pharmacol Rev 1999; 51:159-212.
4. Julius D, Basbaum AI. Molecular mechanisms of nociception. Nature 2001; 413:203-210.
5. Zygmunt PM, Peterson J, Andersson DA, Chuang H, Sorgard M, DiMarzo V, et al. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 1999; 400:452-457.
6. Wang Y, Kaminski NE, Wang DH. VR1-mediated depressor effects during high-salt intake: role of anandamide. Hypertension 2005; 46:986-991.
7. Haddy FJ, Pamnani MB. Role of dietary salt in hypertension. J Am Coll Nutr 1995; 14:428-438.
8. Alderman MH. Salt, blood pressure, and human health. Hypertension 2000; 36:890-893.
9. Frohlich ED, Chien Y, Sesoko S, Pegram B. Relationship between dietary sodium intake, hemodynamics, and cardiac mass in SHR and WKY rats. Am J Physiol 1993; 264:R30-R34.
10. Morimoto A, Uzu T, Fujii T, Nishimura M, Kuroda S, Nakamura S, et al. Sodium sensitivity and cardiovascular events in patients with essential hypertension. Lancet 1997; 350:1734-1737.
11. Raij L. Nitric oxide, salt sensitivity and cardiorenal injury in hypertension. Semin Nephrol 1999; 19:296-303.
12. Wang DH, Li JP, Qiu JX. Salt sensitive hypertension induced by sensory denervation: introduction of a newmodel. Hypertension 1998; 32:649-653.
13. Wang Y, Wang DH. A novel mechanism contributing to development of Dahl salt-sensitive hypertension: role of the transient receptor potential vanilloid type 1. Hypertension 2006; 47:609-614.
14. Huang SM, Bisogno T, Trevisani M, Al-Hayani A, De Petrocellis L, Fezza F, et al. An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc Natl Acad Sci U S A 2002; 99:8400-8405.
15. De Petrocellis L, Bisogno T, Davis JB, Pertwee RG, Di Marzo V. Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin-like activity. FEBS Lett 2000; 483:52-56.
16. Bisogno T, Melck D, Bobrov MY, Gretskaya NM, Bezuglov VV, De Petrocellis L, Di Marzo V. N-acyl-dopamines: novel synthetic CB1 cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochem J 2000; 351:817-824.
17. Hwang SW, Cho H, Kwak J, Lee S, Kang CJ, Jung J, et al. Direct activation of capsaicin receptors by products of lipoxygenases: endogenous capsaicin-like substances. Proc Natl Acad Sci U S A 2000; 97:6155-6160.
18. Smart D, Gunthorpe MJ, Jerman JC, Nasir S, Gray J, Muir AI, et al. The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1). Br J Pharmacol 2000; 129:227-230.
19. Wang Y, Wang DH. Prevention of endothelin-1-induced increases in blood pressure: role of endogenous CGRP. Am J Physiol 2004; 287:H1868-H1874.
20. Lake KD, Martin BR, Kunos G, Varga K. Cardiovascular effects of anandamide in anesthetized and conscious normotensive and hypertensive rats. Hypertension 1997; 29:1204-1210.
21. Akerman S, Kaube H, Goadsby PJ. Vanilloid type 1 receptor (VR1) on trigeminal sensory nerve fibers play a minor role in neurogenic dural vasodilation, and are involved in capsaicin-induced dural dilation. Br J Pharmacol 2003; 140:718-724.
22. Tognetto M, Amadesi S, Harrison S, Creminon C, Trevisani M, Carreras M, et al. Anandamide excites central terminals of dorsal root ganglion neurons via vanilloid receptor-1 activation. J Neurosci 2001; 21:1104-1109.
23. Donnerer J, Lembeck F. Analysis of the effects of intravenously injected capsaicin in the rat. Naunyn Schmiedebergs Arch Pharmacol 1982; 320:54-57.
24. Yeh JL, Lo YC, Wang Y, Chen IJ. Cardiovascular interactions of nonivamide, glyceryl nonivamide, capsaicin analogues, and substance P antagonist in rats. Brain Res Bull 1993; 30:641-648.
25. Lo YC, Yeh JL, Wu JR, Yang JM, Chen SJ, Chen IJ. Autonomic and sensory cardiovascular activities of nonivamide: intrathecal administration of clonidine. Brain Res Bull 1994; 35:15-22.
26. Guo A, Vulchanova L, Wang J, Li X, Elde R. Immunocytochemical localization of the vanilloid receptor 1 (TRPV1): relationship to neuropeptide, the P2X3 purinoceptor and IB4 binding sites. Eur J Neurosci 1999; 11:946-958.
27. Wang DH, Wu W, Lookingland KJ. Degeneration of capsaicin-sensitive sensory nerves leads to increased salt sensitivity through enhancement of sympathoexcitatory response. Hypertension 2001; 37:440-443.
28. Brain SD, Williams TJ, Tippins JR, Morris HR, MacIntyre I. Calcitonin gene-related peptide is a potent vasodilator. Nature 1985; 313:54-56.
29. Edvinsson L, Fredholm BB, Hamel E, Jansen I, Verrecchia C. Perivascular peptides relax cerebral arteries concomitant with stimulation of cyclic adenosine monophosphate accumulation or release of an endothelium-derived relaxing factor in the cat. Neurosci Lett 1985; 58:213-217.
30. Gray DW, Marshall I. Human α-CGRP stimulates adenylate cyclase and guanylate cyclase and relaxes rat thoracic aorta by releasing nitric oxide. Br J Pharmacol 1992; 107:691-696.
31. + channels. Nature 1990; 344:770-773.
32. Oh-hashi Y, Shindo T, Kurihara Y, Imai T, Wang Y, Morita H, et al. Elevated sympathetic nervous activity in mice deficient in aCGRP. Circ Res 2001; 89:983-990.
33. DiPette DJ, Schwarzenberger K, Kerr N, Holland OB. Dose dependent systemic and regional hemodynamic effects of calcitonin gene-related peptide. Am J Med Sci 1989; 297:65-70.
34. McEwan JS, Legon SJ, Wimalawansa SJ, Zaidi M, Dollery CT, MacIntyre I. Calcitonin gene-related peptide: a review of its biology and relevance to the cardiovascular system. In: Laragh JH, Brenner BM, Kaplan NM, editors. Endocrine mechanisms in hypertension. New York: Raven Press Publishers; 1989. pp. 287-304.
35. Supowit SC, Rao A, Bowers MC, Zhao H, Fink G, Steficek B, et al. Calcitonin gene-related peptide protects against hypertension-induced heart and kidney damage. Hypertension 2005; 45:109-114.
36. Supowit SC, Zhao H, Hallman DM, DiPette DJ. Calcitonin gene-related peptide is a depressor of deoxycorticosterone-salt hypertension in the rat. Hypertension 1997; 29:945-950.
37. Supowit SC, Zhao H, Hallman DM, DiPette DJ. Calcitonin gene-related peptide is a depressor in subtotal nephrectomy hypertension. Hypertension 1998; 31:391-396.
38. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990; 346:561-564.
39. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993; 365:61-65.
40. Varga K, Lake KD, Huangfu D, Guyenet PG, Kunos G. Mechanism of the hypotensive action of anandamide in anesthetized rats. Hypertension 1996; 28:682-686.
41. O'Sullivan SE, Kendall DA, Randall MD. Characterisation of the vasorelaxant properties of the novel endocannabinoid N-arachidonoyldopamine (NADA). Br J Pharmacol 2004; 141:803-812.